LYS006   Click here for help

GtoPdb Ligand ID: 11205

Synonyms: LYS-006
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: LYS006 is one of the chemical structures claimed in a Novartis patent as inhibitors of leukotriene A4 hydrolase (LTA4H) [1]. Both the (R) and (S) stereoisomers are claimed (examples 3 and 29 respectively). Both isomers have similar inhibitory potency in vitro. The (3S)-enantiomer was disclosed as LYS006 in 2021 [2], and at that point we modified our record to reflect this updated information. LYS006 is being developed for immunomodulatory action that can be applied to acute and chronic inflammation and autoinflammatory disorders.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 129.04
Molecular weight 392.08
XLogP 2.82
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N[C@H](Cn1nnc(n1)c1ccc(cc1)Oc1ncc(cc1F)Cl)CC(=O)O
Isomeric SMILES N[C@H](Cn1nnc(n1)c1ccc(cc1)Oc1ncc(cc1F)Cl)CC(=O)O
InChI InChI=1S/C16H14ClFN6O3/c17-10-5-13(18)16(20-7-10)27-12-3-1-9(2-4-12)15-21-23-24(22-15)8-11(19)6-14(25)26/h1-5,7,11H,6,8,19H2,(H,25,26)/t11-/m0/s1
Immunopharmacology Comments
LYS006 a clinical stage inhibitor of leukotriene A4 hydrolase (LTA4H) that It is being developed for potential to treat to acute and chronic inflammation and autoinflammatory disorders. It blocks conversion of leukotriene A4 to leukotriene B4, thus preventing neutrophil activation and mobilisation to sites of inflammation